Novartis Completes Major US Expansion Plan with Seventh Facility to Strengthen End to End Manufacturing Capabilities

Novartis Completes Major US Expansion Plan with Seventh Facility to Strengthen End to End Manufacturing Capabilities

(IN BRIEF) Novartis has finalized its US manufacturing and research expansion plan with the announcement of a seventh new facility in Morrisville, North Carolina, dedicated to producing active pharmaceutical ingredients for solid-dose medicines and RNA therapies. The move is part of a broader $23 billion investment initiative aimed at strengthening domestic production and ensuring end-to-end manufacturing capabilities within the US. Over the past year, the company has made substantial progress, including launching new research and manufacturing sites in California, Texas, Florida, and North Carolina, as well as expanding existing facilities. These investments are designed to enhance supply chain resilience, support the development of advanced therapies, and improve patient access to innovative medicines. Novartis is positioning itself to deliver a fully integrated manufacturing network across multiple technology platforms, marking a significant milestone in its operational strategy.

(PRESS RELEASE) BASEL, 30-Apr-2026 — /EuropaWire/ — Novartis has completed the rollout of its US manufacturing and research expansion strategy with plans for a seventh new facility, reinforcing its long-term commitment to local production and innovation. The latest addition will be built in Morrisville, North Carolina, and will focus on manufacturing active pharmaceutical ingredients (APIs) for solid-dose medicines such as tablets and capsules, as well as RNA-based therapies.

The new 56,200-square-foot site represents a significant step in strengthening Novartis’ ability to manage the full production lifecycle within the United States—from the creation of active ingredients to the delivery of finished medicines. With this addition, the company will expand its North Carolina footprint to five facilities across three locations, further enhancing its manufacturing capabilities in the region.

The announcement completes a broader $23 billion investment initiative launched in 2025, under which Novartis committed to building seven new facilities across the US. This strategy is designed to ensure that key medicines for US patients are developed, produced, and delivered domestically, improving supply chain resilience and accelerating access to innovative treatments.

Chief Executive Officer Vas Narasimhan highlighted that the company is establishing a fully integrated US-based network capable of supporting advanced therapeutic platforms. By creating a connected infrastructure, Novartis aims to streamline development and production processes while ensuring patients receive timely access to new therapies.

Over the past year, Novartis has advanced multiple projects under this investment plan. In early 2026, the company began construction of a biomedical research center in San Diego, expanding its research presence alongside its existing operations in Cambridge, Massachusetts. During the same period, new manufacturing facilities were announced in Denton, Texas, and Winter Park, Florida, to produce radioligand therapies for cancer treatment, extending the company’s network for these specialised medicines.

Additional milestones include the launch of a radioligand therapy manufacturing site in Carlsbad, California, as well as ongoing expansions of facilities in Indianapolis, Indiana, and Millburn, New Jersey. These developments are intended to meet growing demand for advanced cancer treatments while supporting future innovation.

In late 2025, Novartis also initiated construction of a major production hub in North Carolina, which will support the manufacturing and packaging of medicines across a wide range of therapeutic areas, including oncology, immunology, neuroscience, and cardiovascular and metabolic diseases.

Through these combined investments, Novartis is moving toward establishing end-to-end manufacturing capabilities in the US across all major technology platforms, including small molecules, biologics, radioligand therapies, RNA-based treatments, and cell and gene therapies. This integrated approach represents a significant milestone for the company, enabling greater control over its production processes and enhancing its ability to deliver innovative medicines at scale.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” or similar expressions, or by express or implied discussions regarding: potential new products; potential new indications for existing products; potential product launches or potential future revenues from any such products; results of ongoing clinical trials; potential future sales or earnings; or strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that such products will be commercially successful in the future. Nor can there be any guarantee that the expected benefits from the plans and investments described in this press release will be achieved in the expected timeframe, or at all. In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the success of our key products, commercial priorities and strategy; research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; the development or adoption of new technologies, including artificial intelligence, and new business models; potential significant breaches of information security or disruptions of our information technology systems; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future global exchange rates; future demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

About Novartis 
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

Media Contacts:

SOURCE: Novartis